In COPD – also known as Chronic Obstructive Pulmonary Disease – patients often experience serious exacerbations, or flare-ups, that complicate breathing. These episodes can unfortunately lead to emergency room treatment or stays in the hospital and may worsen COPD. Even though current medication is considered adequate, there are a few patients who may benefit from new trial drugs.
“The DYNAGITO COPD clinical trial will enable participants to learn whether the investigational drug combination of Tiotropium and Olodaterol can help them and others living with severe COPD,” explained Dr. Jeffrey Wayne, Medical Director for Clinical Trials Research. “We encourage people with COPD to contact us to learn more about the DYNAGITO COPD clinical trial.”
Tiotropium is an inhaled bronchodilator available worldwide as a verified prescription medicine for COPD. Triotropium has shown to reduce the amount of COPD exacerbations in patients. Olodaterol is also an inhaled bronchodilator but has been proven more effective to improve COPD patients with their breathing.
Dr. Jeffrey D. Wayne is a medical researcher for more than 20 years in the Sacramento area. Clinical Trials Research also has a research facility in Lincoln, California.
If you’re interested in participating in this trial, read the following criteria carefully:
To be a part of DYNAGITO COPD research study, individuals have to be at least 40 years old; smoked; diagnosed with severe COPD; and experienced a moderate-to-severe COPD exacerbation episode in the last year treated with systematic corticosteroids, antibiotics or hospitalization.
The trial will last 55 weeks and include seven visits to the study site and four phone calls from the clinical staff. Participants will be required to take medical exams and blood samples for lab tests; have breathing/lung capacity measured; and receive demonstrations on how to use the investigational inhaler device.
For patients who would like to learn more, they can contact Dr. Wayne at 16-434-8230 or visit Clinical Trials Research page about COPD research.